- cafead May 31, 2024 at 11:02: AM
via Ultragenyx Pharmaceutical on Thursday said its potential treatment for glycogen storage disease type 1a met multiple endpoints in a clinical study.
The Novato, Calif.-based biopharmaceutical company said its gene therapy DTX401 had resulted in a statistically significant and clinically meaningful reduction in daily cornstarch intake after 48 weeks, which was the study's primary endpoint.
article source
The Novato, Calif.-based biopharmaceutical company said its gene therapy DTX401 had resulted in a statistically significant and clinically meaningful reduction in daily cornstarch intake after 48 weeks, which was the study's primary endpoint.
article source